
BiBB Engages EUS Pioneer Professor Peter Vilmann as Scientific Advisor

BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, today announces that Professor Peter Vilmann, a world-renowned pioneer who performed the first endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in 1991, will serve as Scientific Advisor. He brings extensive expertise in endoscopic ultrasound-guided biopsy and therapy and will provide scientific support to the Company while contributing to its clinical roadmap.

“We are very pleased to have the opportunity to benefit from the expertise of a true pioneer in the field of EUS biopsy. Professor Vilmann is an accomplished endoscopist and the inventor of the world’s first dedicated EUS biopsy needle. His involvement will be highly valuable as we advance the development and clinical adoption of EndoDrill, says Dr. Charles Walther, Founder and CMO of BiBBInstruments.

About Professor Peter Vilmann

Professor Peter Vilmann is a world-renowned pioneer in endoscopic ultrasound (EUS). In 1991, he performed the first EUS-guided fine needle aspiration biopsy (FNA) and co-invented the first dedicated EUS biopsy needle. His work has been central to establishing EUS-guided biopsy, as well as EBUS-TBNA, as recognized global gold standards in cancer diagnostics.

With more than three decades at the forefront of innovation, Professor Vilmann has authored numerous scientific contributions, trained generations of endoscopists, and delivered over 400 international lectures. His current research continues to focus on advancing diagnostic and therapeutic EUS procedures, with a strong focus on pancreatic lesions.

About EndoDrill® GI

EndoDrill® GI is the world’s first FDA-cleared powered biopsy instrument for endoscopic ultrasound (EUS). Unlike conventional manual FNA/FNB needles, it features a motorized rotating tip that extracts intact core tissue samples, delivering superior histological yield and enabling molecular analysis. The system received 510(k) clearance in the U.S. in 2023 and CE marking in Europe in 2024. It is currently undergoing clinical evaluation in both regions, with a U.S. launch in collaboration with TaeWoong Medical USA set to begin in autumn 2025.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB

BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, the world’s first line of powered endoscopic biopsy instruments. EndoDrill® is designed to collect core tissue samples (CNB) with high diagnostic

accuracy, aiming to improve the diagnosis of cancers in the stomach, pancreas, liver, lung, and bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and rapidly growing segments of endoscopy. BiBB received 510(k) clearance from the U.S. FDA for its lead product, EndoDrill® GI, in 2023. In 2024, CE marking under the EU Medical Device Regulation (MDR) was granted for all three product variants – EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO – making EndoDrill® the first powered biopsy system cleared in both the U.S. and Europe. The U.S. launch of EndoDrill® GI is set to begin in autumn 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile, single-use biopsy instruments and a proprietary motorized drive unit. BiBB was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund, Sweden, and is listed on Spotlight Stock Market (ticker: BIBB).